Tirzepatide: difference between revisions
Diff·revision 20 → 21·07:44, 8 May 2025
Difference between revision 20 and revision 21 of Tirzepatide. 7 lines changed; the page grew by 1,201 bytes.
| Revision 20 — 21:58, 14 Apr 2025 ArchiveBot (talk) bot: expand DOI to full citation 6,572 bytes +243 | Revision 21 — 07:44, 8 May 2025 MolarMassMaeve (talk) add a hatnote pointing at the analogue with the similar name 7,773 bytes +1,201 | ||
|---|---|---|---|
| 56 | The five-step escalation from 2.5 mg with four weeks at each step exists for tolerability rather than efficacy, and compressing it predictably increases gastrointestinal events. See [[Dose escalation schedule]]. | 56 | The five-step escalation from 2.5 mg with four weeks at each step exists for tolerability rather than efficacy, and compressing it predictably increases gastrointestinal events. See [[Dose escalation schedule]]. |
| 57 | 57 | ||
| + | 58 | == Material outside licensed supply == | |
| + | 59 | Tirzepatide is widely offered by research-chemical suppliers. The same documentary cautions apply as for any peptide of this class, with one addition specific to it: at 4,813 g·mol⁻¹ and with two Aib residues and a C-20 diacid, it is a demanding synthesis, and crude purity before [[Preparative HPLC purification|preparative purification]] is lower than for shorter peptides.{{r|usp1503}} | |
| + | 60 | ||
| + | 61 | Identity is therefore worth as much attention as purity. A purity figure by [[Area percent purity|area percent]] establishes only that one peak dominates a chromatogram; it does not establish that the peak is tirzepatide. Confirmation by [[Mass spectrometry|mass spectrometry]] with a reported observed mass is the minimum that distinguishes the intended molecule from a deletion sequence differing by one residue, and deletion sequences co-elute readily on a short gradient.{{r|reports}} | |
| + | 62 | ||
| 58 | == References == | 63 | == References == |
| 59 | {{reflist}} | 64 | {{reflist}} |
| ⋮ | ⋮ | ||
| 61 | <ref name="frias2021">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> | 66 | <ref name="frias2021">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> |
| 62 | <ref name="jastreboff2022">Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide once weekly for the treatment of obesity." ''New England Journal of Medicine'' 387(3):205–216 (2022). DOI:10.1056/NEJMoa2206038. PMID 35658024.</ref> | 67 | <ref name="jastreboff2022">Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide once weekly for the treatment of obesity." ''New England Journal of Medicine'' 387(3):205–216 (2022). DOI:10.1056/NEJMoa2206038. PMID 35658024.</ref> |
| + | 68 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| + | 69 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | |
| 63 | 70 | ||
| 64 | == See also == | 71 | == See also == |